Pages
Posts by category
My Templates
News & Press
- Lotus Response to Coronavirus (COVID-19)
- Neil Singla, MD, CEO at Lotus Clinical Research, Speaks on Opioid Sparing Outcomes
- Lotus Clinical Research Adopts Veeva Vault CDMS to Improve Efficiency and Speed Study Timelines Across Clinical Teams
- Avenue Therapeutics Positive Topline Data from a Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
- Lotus' CEO, Neil Singla, MD on Avenue Therapeutics Key Opinion Leader Panel for Postoperative Pain
- Lotus Clinical Research Announces the Addition of Drs. Lee Simon and Allan Green
- Accelerating Development of Non-Opioid Pain Medicines
- Registration Open for American Pain Society's Conference on Analgesic Trials
- Lotus Clinical Research Executive to Present on Opioid Sparing Outcomes at 19th Annual Pain Therapeutics Conference
- Lotus Clinical Research Adds Peggy Schrammel as Senior Vice President, CRO Services
- Development of Long-Acting Local Anesthetics
- Lotus Clinical Research LLC Receives Private Equity Backing
- Dr. Neil Singla speaks to the Wall Street Journal about analgesic research seeking opioid alternatives
- US Surgeon General to Speak at APS Conference on Analgesic Trials
- American Pain Society's Conference on Analgesic Trials Confirmed Presenters Announced and Registration Open
- Lotus Clinical Research Executive to Present on Opioid Sparing Endpoints at 11th Annual Pain & Migraine Therapeutics Summit
- New Clinical Trial Data for Novel Clinical-Stage Therapies for Pain to be Shared at Annual Pain and Migraine Therapeutics Summit
- Analgesic Experts Converge to Push Forward on Advancing Pain Research
- Neil Singla, MD, Chief scientific Officer of Lotus Clinical Research to chair the American Pain Society’s 2nd annual Conference on Analgesic Trials
- American Pain Society’s 2nd annual Conference
- Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam
- Results from Pivotal Phase III-Clinical Trial of IV Meloxicam
- Recro Pharma IV Meloxicam-Rapid and sustained pain relief following bunionectomy surgery
- Neil Singla, MD, Chief Scientific Officer of Lotus Clinical Research
- Neil Singla presents at Pain & Migraine Therapeutics Summit
- iX Biopharma
- AcelRx Pharmaceuticals' ARX-04 met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial
- Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative Pain
- Dr. Neil Singla chairs a new special interest group at the IASP
- WEBINAR: Expert Review of Recently Released FDA Analgesic Draft Guidance
- Lotus to Present Scientific Poster at APS 2013
- Dr. Neil Singla and Dr. Nathaniel Katz to chair the Clinical Trials SIG Session at APS 2013
- Dr. Neil Singla to present at the 6th Annual Pain Therapeutics Summit in San Jose, CA
- Dr. Neil Singla and Dr. Nathaniel Katz to chair the Clinical Trials SIG Session at APS 2012
- ProFibrix US Phase II Study with FibrocapsTM Meets All Primary and Secondary Endpoints
- Lotus Clinical Research,Lotus to Sponsor CHI’s Accelerating Proof-of-Concept Conference in Philadelphia
- Adolor Corporation Announces Positive Results from Phase 2 Program in OIC
- Lotus Clinical Research to present Assay Sensitivity Case Study at the upcoming ACCP Conference
- Cumberland Pharmaceuticals IV Ibuprofen Lessens Morphine Use
- Caldolor Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
- Cumberland Pharmaceuticals Pre andPost-Operative Use of Caldolor Significantly Reduces Pain and Opioid Use in Newly Published Study
- AcelRx Pharmaceuticals Inc Announces Positive Phase 2 Results
- Key Caldolor Orthopedic Data to Be Presented at American Academy of Orthopedic Surgeons Annual Meeting
- Cleviprex Results Reported From Study In Patients With Intracerebral Hemorrhage
- Roxro Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
- The 2008 Pipeline Report – Breakthrough NSAIDS
- New Methods of reducing Pain Identified at Huntington
- Roxro Pharma’s Phase 3 Intranasal Analgesic Data Receives Excellence Award
- Physicians Practice
- Roxio Pharma Inc.
Resource Library
- How Sites and Sponsors in the Clinical Research Industry Can Best Contribute to Determining Fair Market Value
- Method to the Madness: The Impact of Form Design on Data Collection
- Efficacy and Safety of Intravenous Meloxicam in Subjects with Moderate-to-Severe Pain Following Abdominoplasty
- Staff Education - Mitigation of Placebo Response Phenomenon in Analgesic Clinical Trials
- Exploring the Interplay between Rescue Drugs, Data Imputation, and Study Outcomes Conceptual Review and Qualitative Analysis of an Acute Pain Data Set
- WEBINAR: Bunionectomy Part 1: Model Overview
- Mastopexy Bleeding Model
- Mitigation of Placebo Response Phenomenon in Analgesic Clinical Trials
- Abdominoplasty Bleeding Model
- Patient Education - Mitigation of Placebo Response Phenomenon in Analgesic Clinical Trials
- WEBINAR: Mitigation of Placebo Response Phenomenon in Analgesic Clinical Trials
- Maximizing Effect Size Video
- Expert Review of 2014 Released FDA Analgesic Draft Guidance
- Mitigation of Placebo Response Phenomenon in Analgesic Clinical Trials
- ACTTION Systematic Review and Meta-Analysis
- Axelopran Phase 2b Study
- Delayed-onset muscle soreness pilot study
- Bunionectomy Part 1: Model Overview
- Webinar: Handling Missing Data in Analgesic Clinical Trials
- Expert Review of Recently Released FDA Analgesic Draft Guidance
- Comparison of clinical and experimental characteristics of surgical pain models
- TD-1211 Phase 2b Study
- Phase 3 Study - MNK-795 Oxycodone/Acetaminophen Extended-Release Tablets in Acute Pain Model
- TD-1211 Phase 2b Study -Opiod-induced Constipation Withdrawal
- Phase 3 Study - Safety and Analgesic Efficacy of MNK-795 Controlled-Release Oxycodone/Acetaminophen Tablets
- Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of of MNK-795
- Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Controlled Release Oxycodone/Acetaminophen Tablets (CR OC/APAP) in an Acute Pain Model
- 5-Week Phase 2b Opioid-Induced Constipation Study
- Phase 2b Study in Opioid Induced Constipation
- Phase 2b Study -Bowel Movement Frequency and Constipation-Related Symptom in Patients with Opioid-Induced Constipation
- TD-1211 -Multiple Treatment Administration Strategies in Patients with Opioid-Induced Constipation
- Durable Increase in Bowel Movement Frequency in a 5-Week Phase 2b Opioid-Induced Constipation Study
- Phase 2b Study on withdrawal in Opioid-Induced Constipation
- Review of sensetivity of efficacy endpoints TOTPAR and SPID in acute pain.
- Safety and efficacy of tanezumab for chronic low back pain
- Long-term safety and efficacy of tanezumab as treatment for chronic low back pain
- Injectable Formulation of Diclofenac Compared with Intravenous Ketorolac or Placebo
- Safety and Immunogenicity of Recombinant Human Thrombin: Pooled Analysis of 10 Clinical Trials
- Improvement in Bowel Movement Frequency and Bristol Stool Scores in Phase 2b OIC Study
- OIC Phase 2b Study - Bowel Movement Frequency and Bristol Stool Scores
- Phase 2b Evaluation of TD-1211 in Opioid-Induced Constipation
- OIC Phase 2b Study-Improvement in Bowel Movement Frequency Without Impacting Analgesia
- Plasma and Cerebrospinal Fluid Pharmacokinetic Parameters After Administration of Acetaminophen
- Recombinant Human Thrombin with Absorbable Gelatin Powder when Applied as a Flowable Topical Hemostat
- Chronic Opioid Therapy for Noncancer Pain
- Increasing Effect Size in Analgesic Trials
- 2 Phase 2 Trials in Patients with Opioid-induced Constipation
- Plasma and Cerebrospinal Fluid Pharmacokinetic Parameters after Single-Dose Administration of Intravenous, Oral or Rectal Acetaminophen
- TD-1211 Demonstrates Constipation-relieving Effects in Opioid-Induced Constipation Patients
- DepoFoam Bupivacaine Exhibits Pharmacokinetic Properties
- EXPAREL Exhibits Pharmacokinetic Properties
- Intravenous, Oral or Rectal Acetaminophen Single-Dose Administration
- TD-1211- Peripheral Selectivity and Constipation-Relieving Effects in Patients
- Phase 2 Study-Clinical Efficacy, Safety, and Tolerability of ARX-03 Sublingual Sufentanil/Triazolam
- Oxycodone in Relieving Moderate-to-Severe Postoperative Pain
- Efficacy and Safety of oxycodone HCI/niacin tablets
- Clinical Therapeutics Volume 32
- Multiple-Dose Intravenous Acetaminophen in Adults
- Recombinant Human Thrombin After Subsequent Surgical Re-exposure
- Use of Pregabalin for Postoperative Pain: Outcomes in 2 Trials
- Assay Sensitivity Case Study
- Intravenous-Ibuprofen Pian Trial with Post-Operative Orthopedic Adult Patients
- Intranasal ketorolac for acute postoperative pain
- Phase 2 Study-Oral Neurokinin-1 Receptor Antagonist Casopitant for Prevention of Postoperative and Postdischarge Nausea and Vomiting in High-risk Patients
- Pregabalin in the Treatment of Postoperative Pain
- Phase 2 Study: Sublingual Sufentanil NanoTab™ Following Major Abdominal Surgery
- Ibuprofen Injection for Treatment of Pain in Post-Operative Orthopedic Patients
